Evidence map›Paper›PMID 42304044›Full record

ArticleScientific reports2026

Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

Murat Günaltılı, Murad Guliyev, Zeliha Birsin, Emir Çerme, Vali Aliyev, Gülin Alkan Şen, Ali Kaan Güren, Emre Özge, İlkay Gültürk, Rumeysa Çolak and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Murat GünaltılıDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey. muratgunaltili@gmail.com.ORCID https://orcid.org/0000-0001-6116-3936
Murad GuliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Zeliha BirsinDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Emir ÇermeDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Vali AliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Gülin Alkan ŞenDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Ali Kaan GürenDivision of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, 34899, Istanbul, Turkey.
Emre ÖzgeDepartment of Medical Oncology, University of Health Science, Istanbul Training and Research Hospital, 34098, Istanbul, Turkey.
İlkay GültürkDepartment of Medical Oncology, University of Health Science, Istanbul Training and Research Hospital, 34098, Istanbul, Turkey.
Rumeysa ÇolakDepartment of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147, Istanbul, Turkey.
Mesut YılmazDepartment of Medical Oncology, University of Health Science, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 34147, Istanbul, Turkey.
Özkan AlanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
İbrahim Vedat BayoğluDivision of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, 34899, Istanbul, Turkey.
Zeynep Hande TurnaDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.
Nebi Serkan DemirciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, 34098, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity has been associated with inferior outcomes in early-stage breast cancer, but its clinical relevance in metastatic disease treated with CDK4/6 inhibitors remains uncertain. We retrospectively analyzed 332 patients with hormone receptor-positive/HER2-negative metastatic breast cancer who received first-line ribociclib or palbociclib plus endocrine therapy between 2018 and 2023. Patients were stratified by baseline BMI: <30 kg/m

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ObesityProtein Kinase InhibitorsAdultAgedAminopyridinesBody Mass IndexFemaleHumansMiddle AgedNeoplasm MetastasisPiperazinesPurinesPyridinesAminopyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesribociclibBody mass indexBreast cancerCDK4/6 inhibitorsPrognosisSurvival

Identifiers

PMID42304044
PMCPMC13482817

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.